Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O’Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781):217–223. https://doi.org/10.1038/s41586-019-1694-1 (Epub 2019 Oct 30 PMID: 31666701)

CAS  Article  PubMed  Google Scholar 

Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang HL, Wurz RP, Xue M, Yang KC, Achanta P, Bartberger MD, Canon J, Hollis LS, McCarter JD, Mohr C, Rex K, Saiki AY, San Miguel T, Volak LP, Wang KH, Whittington DA, Zech SG, Lipford JR, Cee VJ (2020) Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem 63(1):52–65. https://doi.org/10.1021/acs.jmedchem.9b01180 (Epub 2019 Dec 24 PMID: 31820981)

CAS  Article  PubMed  Google Scholar 

LUMAKRAS [package insert] Thousand Oaks, CA: Amgen Inc. 2021

Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29(3):408–413. https://doi.org/10.1038/clpt.1981.56 (PMID: 6781809)

CAS  Article  PubMed  Google Scholar 

Penner N, Klunk LJ, Prakash C (2009) Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30(4):185–203. https://doi.org/10.1002/bdd.661 (PMID: 19544285)

CAS  Article  PubMed  Google Scholar 

Dahal UP, Rock BM, Rodgers J, Shen X, Wang Z, Wahlstrom JL (2022) Absorption, distribution, metabolism and excretion of [14C]-sotorasib in rats and dogs: interspecies differences in absorption, protein conjugation and metabolism. Drug Metab Dispos. DMD-AR-2021-000798. https://doi.org/10.1124/dmd.121.000798. Epub ahead of print. PMID: 35153196

Ishida K, Werner JA, Davies R, Fan F, Thomas B, Wahlstrom J, Lipford JR, Monticello T (2021) Nonclinical safety profile of sotorasib, a KRASG12C-specific covalent inhibitor for the treatment of KRAS p.G12C-mutated cancer. Int J Toxicol. 40(5):427–441. https://doi.org/10.1177/10915818211022965 (Epub 2021 Jun 17 PMID: 34137282)

CAS  Article  PubMed  Google Scholar 

Roffel AF, van Marle SP, van Lier JJ, Hartstra J, van Hoogdalem EJ (2016) An evaluation of human ADME and mass balance studies using regular or low doses of radiocarbon. J Labelled Comp Radiopharm 59(14):619–626. https://doi.org/10.1002/jlcr.3473 (PMID: 28000265)

CAS  Article  PubMed  Google Scholar 

Lozac’h F, Fahrni S, Maria D, Welte C, Bourquin J, Synal HA, Pearson D, Walles M, Camenisch G (2018) Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm. Bioanalysis 10(5):321–339. https://doi.org/10.4155/bio-2017-0216 (Epub 2018 Feb 16 PMID: 29451392)

CAS  Article  PubMed  Google Scholar 

Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69(4):1051–1061. https://doi.org/10.1007/s00280-011-1803-9 (Epub 2011 Dec 27 PMID: 22200729)

CAS  Article  PubMed  Google Scholar 

Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G (2015) Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43(2):289–297. https://doi.org/10.1124/dmd.114.060061 (Epub 2014 Dec 8 PMID: 25488930)

CAS  Article  PubMed  Google Scholar 

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P (2016) Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44(8):1201–1212. https://doi.org/10.1124/dmd.115.069203 (Epub 2016 May 25 PMID: 27226351)

CAS  Article  PubMed  Google Scholar 

Sabbioni G, Turesky RJ (2017) Biomonitoring human albumin adducts: the past, the present, and the future. Chem Res Toxicol 30(1):332–366. https://doi.org/10.1021/acs.chemrestox.6b00366. Epub 2016 Dec 18. PMID: 27989119; PMCID: PMC5241710.

Liu X, Feng D, Zheng M, Cui Y, Zhong D (2020) Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins. Drug Metab Pharmacokinet 35(5):456–465. https://doi.org/10.1016/j.dmpk.2020.07.002 (Epub 2020 Jul 24 PMID: 32847720)

CAS  Article  PubMed  Google Scholar 

Molins-Molina O, Pérez-Ruiz R, Lence E, González-Bello C, Miranda MA, Jiménez MC (2019) Photobinding of triflusal to human serum albumin investigated by fluorescence, proteomic analysis, and computational studies. Front Pharmacol 10:1028. https://doi.org/10.3389/fphar.2019.01028 (PMID: 31616294; PMCID: PMC6764118)

CAS  Article  PubMed  PubMed Central  Google Scholar 

Roffey SJ, Obach RS, Gedge JI, Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39(1):17–43. https://doi.org/10.1080/03602530600952172 (PMID: 17364879)

CAS  Article  PubMed  Google Scholar 

Gardell SJ, Tate SS (1980) Affinity labeling of gamma-glutamyl transpeptidase by glutamine antagonists. Effects of the gamma-glutamyl transferase and proteinase activities. FEBS Lett 122(2):171–174. https://doi.org/10.1016/0014-5793(80)80430-3 (PMID: 6110564)

CAS  Article  PubMed  Google Scholar 

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL (2011) Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39(9):1546–1554. https://doi.org/10.1124/dmd.111.039065 (Epub 2011 Jun 22 PMID: 21697463)

CAS  Article  PubMed  Google Scholar 

Foti RS, Rock DA, Wienkers LC, Wahlstrom JL (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38(6):981–987. https://doi.org/10.1124/dmd.110.032094 (Epub 2010 Mar 4 PMID: 20203109)

CAS  Article  PubMed  Google Scholar 

U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2022) Lumakras NDA 214665 multidisciplinary review and evaluation. Retrieved August 12, 2022 from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf

留言 (0)

沒有登入
gif